Cholecalciferol: 4 agencies, 2003–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused cholecalciferol: all 16 decisive outcomes across 2 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 21.7 years separate the first record, 13 Oct 2003 at SMC (Scotland), from the most recent, 25 Jun 2025 at HAS (France).
No assessment is on file from PBAC (Australia), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 2 of 23 records date from 2023 or later.
5 distinct indication wordings are recorded for cholecalciferol by the agencies that label one in English (AWMSG and SMC).
SMC (Scotland) was first to assess cholecalciferol, on 13 Oct 2003; AWMSG (Wales) did not open a file until 17 Apr 2014 — an unusually long tail of 10.5 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 14 years in total.
2 of the 4 agencies here assessed cholecalciferol more than once, HAS (France) most often at 16 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed cholecalciferol.
The full ledger for cholecalciferol reads 16 recommended, 5 not assessed and 2 other.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 25 Jun 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 14 Dec 2022 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 29 Oct 2015 | In adults, the elderly and adolescents for prevention and treatment of vitamin D deficiency. As an adjunct to specific t… | outside AWMSG criteria | source |
| PHARMAC (New Zealand) | 6 May 2010 | Vitamin D deficiency | PTAC advice: Cost Neutral | source |
| SMC (Scotland) | 13 Oct 2003 | Correction of calcium and Vitamin D deficiency in the elderly | unknown | source |
18 further decisions for cholecalciferol, across 2 agencies, are not shown here. They link to 12 further source documents.
Related molecules
- colecalciferol — same ATC class A11C — Vitamins
- calcium / cholecalciferol — same ATC class A11C — Vitamins
- calcifediol — same ATC class A11C — Vitamins
- alfacalcidol — same ATC class A11C — Vitamins
- osimertinib — also decided by HAS in 2025Q2
- ofatumumab — also decided by HAS in 2025Q2
Coverage: 23 decisions for cholecalciferol from 4 agencies, 2003 to 2025. Data to 7 Sep 2026. ATC class A11C — Vitamins. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.